Optimal Time Interval Between Final Follicular Triggering and Ovum Pickup in ICSI Cycle

Optimal Time Interval Between Final Follicular Triggering by Human Chorionic Gonadotropin and Ovum Pickup and Outcome of Gonadotropin Releasing Hormone Antagonist ICSI Cycles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201911748191910

Enrollment

400

Registered

2019-11-07

Start date

2019-11-30

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female

Interventions

Human chorionic gonadotropin HCG then ovum pickup after 34 hours

Human Chorionic gonadotropin then ovum pickup after 35 hours and 36 hours

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: • Women aged 20 – 35 years with expected normal response to the standard controlled ovarian stimulation undergo ICSI for any cause of infertility.

Exclusion criteria

Exclusion criteria: 1. Cases of polycystic ovaries syndrome (PCOS). 2. Women with history of ovarian hyper-response and/or OHSS in previous ICSI cycle. 3. Women with history of poor ovarian response according to Bologna criteria. 4. Antimullerian hormone level either 4.0 ng/dl. 5. Surgically retrieved sperms. 6. Untreated hydrosalpinges. 7. Congenital uterine abnormalities.

Design outcomes

Primary

Measure	Time frame
•Oocyte retrieval rate: the ratio of the number of cumulus–oocyte–complex (COC) retrieved to the number of follicles =15 mm present on the day of HCG priming. •Percentage of M II oocytes: metaphase II oocytes were defined by the presence of first polar body and round ooplasm.	—

Secondary

Measure	Time frame
• Oocyte morphological abnormalities. • Fertilization rate: defined as the mean number of two pronuclear (2PN) zygotes divided by MII-aspirated oocytes. • Blastocyst rate: defined as the number of blastocysts (day 5/6 embryos) divided by MII- aspirated oocytes. • Embryos quality & grading: cleavage stage embryo and blastocysts will be graded according to corresponding scaling systems. • Implantation rate: calculated as the number of intrauterine gestational sacs observed by transvaginal ultrasonography divided by the number of transferred embryos. • Clinical pregnancy rate: calculated by considering clinical pregnancy, determined by the visualization of a viable gestational sac within the uterine cavity by ultrasound 3– 4 weeks after embryo transfer. • Ongoing pregnancy rate: defined as pregnancy progressing beyond 12 weeks gestation. • OHSS incidence: women who will develop OHSS will be classified according to severity into mild, moderate, severe and critical OHSS.	—

Measure

Time frame

• Oocyte morphological abnormalities. • Fertilization rate: defined as the mean number of two pronuclear (2PN) zygotes divided by MII-aspirated oocytes. • Blastocyst rate: defined as the number of blastocysts (day 5/6 embryos) divided by MII- aspirated oocytes. • Embryos quality & grading: cleavage stage embryo and blastocysts will be graded according to corresponding scaling systems. • Implantation rate: calculated as the number of intrauterine gestational sacs observed by transvaginal ultrasonography divided by the number of transferred embryos. • Clinical pregnancy rate: calculated by considering clinical pregnancy, determined by the visualization of a viable gestational sac within the uterine cavity by ultrasound 3– 4 weeks after embryo transfer. • Ongoing pregnancy rate: defined as pregnancy progressing beyond 12 weeks gestation. • OHSS incidence: women who will develop OHSS will be classified according to severity into mild, moderate, severe and critical OHSS.

—

Countries

Egypt

Contacts

Public ContactMohamed Elmahdy

Assistant Professor of Reproductive endocrinology and infertility

mahdy_moh@yahoo.com0201002413531

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026